
Sign up to save your podcasts
Or


In the United States, about 80 percent of tests used to diagnose C. difficile are PCR assays. So what are the best options to diagnose and treat patients with this infection? To discuss the evolving treatment and evaluation landscape for C. difficile, Dr. Peter Buch is joined by Dr. Paul Feuerstadt, Assistant Clinical Professor at Yale New Haven Hospital.
By ReachMD4.7
1818 ratings
In the United States, about 80 percent of tests used to diagnose C. difficile are PCR assays. So what are the best options to diagnose and treat patients with this infection? To discuss the evolving treatment and evaluation landscape for C. difficile, Dr. Peter Buch is joined by Dr. Paul Feuerstadt, Assistant Clinical Professor at Yale New Haven Hospital.

2,058 Listeners

695 Listeners

496 Listeners

69 Listeners

1 Listeners

3 Listeners

3 Listeners

0 Listeners

6 Listeners

15 Listeners

0 Listeners

0 Listeners

2,442 Listeners

3,332 Listeners

56,419 Listeners

1,153 Listeners

513 Listeners

252 Listeners

217 Listeners

13 Listeners

18 Listeners

33 Listeners